New Skin Lesion Drug Only Scratches Market's Surface, Says Aclaris CEO

Aclaris has surged since the success of two pivotal phase III trials for its lead product candidate for treating skin lesions. The Aclaris CEO says that is only the beginning.
Author:
Publish date:

Shares of Aclaris(ACRS) - Get Report are up more than 22% in the three months since the drugmaker announced the success of two pivotal phase III trials for its lead product candidate, dubbed A-101, for treating skin lesions. Aclaris CEO Dr. Neal Walker said the potential market for this topical drug is over half a billion dollars, and that's only the beginning.